Inozyme
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Inozyme Pharma was a clinical-stage biopharmaceutical company founded in 2015 in Boston as a spinout of Yale University. It developed therapeutics for rare diseases of abnormal mineralization affecting the vasculature, soft tissue and skeleton. Its lead candidate, INZ-701, was a soluble, genetically engineered ENPP1 fusion protein designed as an enzyme replacement therapy for ENPP1 and ABCC6 deficiencies, which cause life-threatening conditions such as generalized arterial calcification of infancy; it was also explored for calciphylaxis in end-stage kidney disease. The company listed on Nasdaq in July 2020 and was acquired by BioMarin Pharmaceutical for $270 million in 2025.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Inozyme Pharma is founded in Boston as a Yale University spinout to develop therapies for rare mineralization disorders.
- IPO
The company goes public on Nasdaq under the ticker INZY, raising about $112 million to advance INZ-701 into Phase 1/2 trials.
- Acquisition
BioMarin Pharmaceutical completes its $270 million acquisition of Inozyme ($4.00 per share); Inozyme is delisted from Nasdaq on July 1, 2025 and becomes a BioMarin subsidiary.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.